You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

DUBLIN, April 23, 2020 /PRNewswire/ -- The "Market Spotlight: Sjgren's Syndrome" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight covers the Sjogren's Syndrome market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals. This research estimates that in 2018, there were approximately 2.3 million prevalent cases of primary Sjogren's syndrome worldwide, and forecasts that number to increase to 2.5 million prevalent cases by 2027. Primary Sjogren's syndrome has a female predominance. Globally, the publisher estimates that in 2018, 90.4% of cases aged 15 years and over were female. Evoxac, a muscarinic agonist specific to M1 receptors, and LO2A, which contains isotonic glycerol and 0.015% sodium hyaluronate, are the only approved drugs for Sjogren's syndrome. The majority of industry-sponsored drugs in active clinical development for Sjogren's syndrome are in Phase II, with only one drug in Phase III. Therapies in development for Sjogren's syndrome focus on a wide variety of targets. The pipeline drugs for Sjogren's syndrome are administered via the oral, intravenous, and subcutaneous routes. The only high-impact upcoming event in the Sjogren's syndrome space is topline Phase II trial results for Benlysta SC. The overall likelihood of approval of a Phase I arthritis asset is 9.9%, and the average probability a drug advances from Phase III is 80%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9 years in the overall autoimmune/immunology space. There have been only four licensing and asset acquisition deals involving Sjogren's syndrome drugs during 2015-2020. The exclusive licensing and collaboration agreement between Eli Lilly and Hanmi for $690m, regarding the development and commercialization of Hanmi's oral BTK inhibitor HM71224 for the treatment of autoimmune and other diseases, was the largest deal. The distribution of clinical trials across Phase I-IV indicates that the majority of trials for Sjogren's syndrome have been in the early and mid-phases of development, with 74% of trials in Phase I-II, and only 26% in Phase III-IV. The US has the highest number of Sjogren's syndrome clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia. Clinical trial activity in the Sjogren's syndrome space is dominated by completed trials. Novartis has the highest number of completed clinical trials for Sjogren's syndrome, with eight trials. Novartis leads the industry sponsors with the highest overall number of clinical trials for Sjogren's syndrome, followed by BristolMyers Squibb. Companies Mentioned Advanz BristolMyers Squibb Eisai Eli Lilly Hanmi Novartis Key Topics Covered OVERVIEWKEY TAKEAWAYSDISEASE BACKGROUNDTREATMENT Dry Eyes Dry Mouth Other Glandular Manifestations Extraglandular Manifestations EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGSRECENT EVENTS AND ANALYST OPINION Iscalimab for Sjogren's Syndrome (January 23, 2020) Mutliple Drugs for Sjogren's Syndrome (October 24, 2019) RSLV-132 for Sjogren's Syndrome (June 13, 2019) KEY UPCOMING EVENTSPROBABILITY OF SUCCESSLICENSING AND ASSET ACQUISITION DEALS Advanz Obtains Two Commercial Products from Eisai PARENT PATENTSCLINICAL TRIAL LANDSCAPE Sponsors by Status Sponsors by Phase BIBLIOGRAPHY Prescription information APPENDIXList of FiguresFigure 1: Trends in Prevalent Cases of Primary Sjogren's Syndrome, 2018-2027Figure 2: Overview of Pipeline Drugs for Sjogren's Syndrome in the USFigure 3: Pipeline Drugs for Sjogren's Syndrome, by CompanyFigure 4: Pipeline Drugs for Sjogren's Syndrome, by Drug TypeFigure 5: Pipeline Drugs for Sjogren's Syndrome, by ClassificationFigure 6: Iscalimab for Sjogren's Syndrome (January 23, 2020): Phase II - Primary SjogrenFigure 7: RSLV-132 for Sjogren's Syndrome (June 13, 2019): Phase II - Study 132-04Figure 8: Key Upcoming Events in Sjogren's SyndromeFigure 9: Probability of Success in the Sjogren's Syndrome PipelineFigure 10: Licensing and Asset Acquisition Deals in Sjogren's Syndrome, 2015-2020Figure 11: Parent Patents in Sjogren's SyndromeFigure 12: Clinical Trials in Sjogren's SyndromeFigure 13: Top 10 Drugs for Clinical Trials in Sjogren's SyndromeFigure 14: Top 10 Companies for Clinical Trials in Sjogren's SyndromeFigure 15: Trial Locations in Sjogren's SyndromeFigure 16: Sjogren's Syndrome Trials StatusFigure 17: Sjogren's Syndrome Trials Sponsors, by PhaseList of TablesTable 1: Prevalent Cases of Primary Sjogren's Syndrome, 2018-2027Table 2: Prevalent Cases of Primary Sjogren's Syndrome, by Gender, 2018Table 3: Prevalence of Primary Sjogren's Syndrome, by Gender, 2018Table 4: Marketed Drugs for Sjogren's SyndromeTable 5: Pipeline Drugs for Sjogren's Syndrome in the USTable 6: Iscalimab for Sjogren's Syndrome (January 23, 2020)Table 7: Mutliple Drugs for Sjogren's Syndrome (October 24, 2019)Table 8: RSLV-132 for Sjogren's Syndrome (June 13, 2019) For more information about this report visit https://www.researchandmarkets.com/r/2rosd0 Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. Media Contact: Research and Markets Laura Wood, Senior Manager [emailprotected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets Related Links http://www.researchandmarkets.com

Answer: 2020 Market Spotlight: Sjogren's Syndrome